<SEC-DOCUMENT>0001493152-23-022917.txt : 20230629
<SEC-HEADER>0001493152-23-022917.hdr.sgml : 20230629
<ACCEPTANCE-DATETIME>20230629161534
ACCESSION NUMBER:		0001493152-23-022917
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230629
DATE AS OF CHANGE:		20230629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LifeMD, Inc.
		CENTRAL INDEX KEY:			0000948320
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
		IRS NUMBER:				760238453
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256911
		FILM NUMBER:		231057565

	BUSINESS ADDRESS:	
		STREET 1:		236 FIFTH AVENUE
		STREET 2:		SUITE 400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		(866) 351-5907

	MAIL ADDRESS:	
		STREET 1:		236 FIFTH AVENUE
		STREET 2:		SUITE 400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CONVERSION LABS, INC.
		DATE OF NAME CHANGE:	20180622

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immudyne, Inc.
		DATE OF NAME CHANGE:	20120514

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMMUDYNE INC
		DATE OF NAME CHANGE:	19950720
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
    Supplement dated June 29, 2023</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    Pursuant to Rule 424(b)(5)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
    Prospectus Dated June 22, 2021)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    No. 333-256911</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_001.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|948320|000149315221014917|logo.jpg" STYLE="height: 42px; width: 203px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 5.35pt; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$60,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc. has entered into an At Market Issuance Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with B. Riley Securities, Inc. (&ldquo;B.
Riley&rdquo;) and Cantor Fitzgerald &amp; Co. (&ldquo;Cantor&rdquo;, and collectively the &ldquo;Agents&rdquo;) relating to the sale
of our common stock offered by this prospectus supplement and the accompanying prospectus, dated June 22, 2021, filed as part of our
registration statement on Form S-3, as amended (File No. 333-256911) (the &ldquo;prospectus&rdquo;). In accordance with the terms of
the Sales Agreement, we may offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $60
million, through or to the Agents, acting as agent or principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock trades on the Nasdaq Global Market under the symbol &ldquo;LFMD.&rdquo; On June 28, 2023, the last reported sale
price of our common stock on the Nasdaq Global Market was $3.94 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2023, we filed a prospectus supplement indicating that we were, at that time, subject to General Instruction I.B.6 of Form
S-3 as a result of our public float being less than $75.0 million, which limited the amount that we were able sell under the registration
statement of which the prospectus, as amended and supplemented, forms a part. In the March prospectus supplement, we disclosed that if
our public float subsequently equals or exceeds $75.0 million such that we may sell additional amounts under the Sales Agreement and
the registration statement of which the prospectus, as amended and supplemented, is a part, and we would file another prospectus supplement
prior to making sales pursuant to the Sales Agreement in excess of the limitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 20, 2023, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $91 million
based upon 33,511,795 shares of outstanding common stock of which 25,620,525 shares are held by non-affiliates, and the
last reported sale price of our common stock of $3.56 per share on June 20, 2023. As a result, our public float has increased above $75.0
million and we are no longer subject to the limitations contained in General Instruction I.B.6. of Form S-3 as of the date of this prospectus
supplement. If we become subject to the offering limits in General Instruction I.B.6 of Form S-3 in the future, we will file another
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus supplement, we have sold an aggregate of 70,786 shares of our common stock for gross proceeds of $493,481
under the Sales Agreement. As a result of such prior sales, as of the date of this prospectus supplement, shares having an aggregate
offering price of up to $59,506,519 remain available for offer and sale under the Sales Agreement through this prospectus supplement
and accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement should be read in conjunction with the prospectus, and is qualified by reference thereto, except to the extent
that the information herein amends or supersedes the information contained in the prospectus. This prospectus supplement is not complete
without, and may only be delivered or utilized in connection with, the prospectus, and any future amendments or supplements hereto or
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves significant risks. You should carefully consider the risk factors beginning on page 5 of the prospectus
and in the documents incorporated by reference in the registration statement concerning factors you should consider before investing
in our common stock. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus supplement or the prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 14pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>B.
    Riley Securities</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Cantor</B></FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 14pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is June 29, 2023. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J ,L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^N:\:^))
M?#>DI+;QJ]Q,^Q-_1>.3[]OSK6O-<TK3YO)N]1MH)<9V/( ?RKS[XEZQINHZ
M=9+97UO.4D8L(W!P,#K6E.%Y*ZT,:T^6#L]2;P=X^U#4=:CT[4]DJSY"2*H4
MJV,\XZCC%>E5X!X+NK>/Q?IS/,B@2=2?8U[F-5T\G O(?^^Q5UX6EHC+#UER
M^_(N5ROBZ1TU7PX%=E#7Z@@'&1E:ZD$, 000>017*>,/^0MX:_[""_S6LZ?Q
M&]7X/N_-'64445!H9NO:.FNZ3)8//)"KD'>GL>X[BK=E;"RL8+42/((8U0.Y
MRS8&,FN6U7Q7K>E?:9I?#;?8X7*^>;D %=V <8[\?G6OJ.K:C!IUI<Z=I)O7
MG4,\8E"[ 0#UQSUJ^65DC)2A=OK\SGK:SE\9:QJDE[?7,5C9W!MH;>!]H)7J
MQ]?_ *];^C^%[+1+I[BVFNG=T*$2R[AC(/3'7BN,\+ZQKEJ^K?9/#[71DOI'
ME G"^6Y/*].<>M=#_P )'XGS_P BD_\ X%#_  K2:ELMOD9TY0MS-:^C.MHK
M/N]9M-,TV.\U.1;7<H)1CD[L9*@#J1[5@?\ "?0R_/:Z)JMQ!_SU2#@CU%9*
M$GLC9U(QW9U]%8NC>*=+UMS#;RM'<CK;S+M<?AW_  K:I--:,I24E=%:>_M[
M:YB@E?:\OW2>E6:Y+QAQ<6_^[_4U-X?U_?ML[Q_FZ1R'O[&K]G[O,CB6,2KR
MI3^1T]%%4=4U2'3+?>_S2'[B>I_PJ$FW9'9.<81<I/1$MW?V]D8Q,^&D.%4<
MFB^OX=.@$T^[:6VC:,\]?Z5P7VR:^U1)IFW,6'X>U=1XM_Y!,?\ UV'_ *":
MT=-)I,\^.-E4IU)Q7P[#_P#A*M.])?\ OD?XU)#XDTV5@ID9">FY?\,U@Z'H
M4.IVCS22LI5]N /8'^M7+GP@-A-M<?,/X7'7\:IQIIV(A6QLHJ:2:_KS.G21
M)4#QLK*>A4Y!IU<'8:A=Z)?&&8-LSAXR?U%=U'(DT221MN1P&4^HK.<.4Z\-
MB573TLUNCYTU1;U=4NA?AOM?F-YN[^]GFLC4"5B0$X!;FOINXTVQNWWW-E;S
M/C&Z2)6/ZBN8\6:1ID5K 8].M%)8_=@4>GM73#$)M*QS8B@Z<'.]['B?A:"2
M?Q#:M&I98B7<CH!@UZ3M;T/Y5<\/6UNFK01K;Q+&S<J$ !^HKOQ8V8.1:P C
MOY8IU:UGL<=+"O%)S3M;0H^'%F71T\[/+$IG^[_^O-9/C#_D+>&O^P@O\UKK
M*Y/QA_R%O#7_ &$%_FM<T7>=SU^3V=%0[6_-'64445F=!SOCK_D3-0^B?^C%
MK8TS_D$V?_7!/_016/XZ_P"1,U#Z)_Z,6MC3/^039_\ 7!/_ $$5;^!>IFOX
MC]/U.;\#?ZS7_P#L)R_SKK)'6*-I'8*B@LQ/8"N3\#?ZS7_^PG+_ #K>UU7?
MP]J2Q_?-K*%QZ[33G\?]>0J;M3OZ_J<QX?L!XIOY?$>J)YL.\I8V[C*HH/WB
M.YS^H/MCMP !@<"O.O#-AXIN/#UI)IVN6T-J5(2,PJ2N&.03M]<UK?V3XV_Z
M&&U_[\+_ /$U4XW>Z(IRM&_*]?Z[FAXD\.1:O;&XMP(=3A&^WN$^5MPZ GT_
ME4OA;66US0HKJ48N$)BG&,8<=?S&#^-97]D^-O\ H8;7_OPO_P 35_PIH-WH
M4%XMY<QSR7$YF)C&!D]>U)VY;-W*C?GNE;N4O&'^OM_]W^IK,ET6>/2XK^-O
M,1@2P Y7G%:?C#_7V_\ N_U-;NB@'1;<$9!4Y!^IJ^9Q@F>8Z$:^*J1E_6Q@
M:;XH:WLVBND:1T'[MO7V-9T45[X@U$DDDG[S'H@K7U'PLTEXKV958G/S*3]S
M_P"M6_86$.GVPAA7_>;NQI.<8J\=V.&&KU9*G6?NQ_'^OP]3A'M?L6L"WW[M
MDF,XQFNG\6_\@F/_ *[#_P!!-8&H_P#(R2?]=?ZUO^+?^03'_P!=A_Z":J7Q
M1,Z22I5TAOA'_D&2_P#78_\ H(KH*Y_PC_R#)?\ KL?_ $$5T%8U/B9Z>#_@
M0]#F/%]LGDPW0&'W;"?7N/ZU0L?$,MI9QP 9" \GZYJWXMO4<Q6:$%D.Y\=C
MV_K^=)I_AQ;FPAFD.UG&<?CQ6JLH+F/.J*<L5+V&]M3K*SM9TS^U+01JX613
ME2>GT-:-%8)M.Z/7G"-2+C+9G-:-X<FL[U;FY=/D^ZJG.372T44Y2<G=DT:$
M*,>6 5R_C:TN7L+/4;2,RRZ=<K<&,=64=?Y#\,UU%%*+L[ERCS*QB6OB[0+J
MW28:I;1[AG9-($9?8@U-_P )-H7_ $&+'_P(7_&LG6=(TS[<6_LZTW,,L?)7
M)/J>*S_[)TW_ *!]I_WY7_"M.6#[F3G-::?B;'CAE?P5?LI!4K&01W&]:V=,
M_P"039_]<$_]!%4];BC?PY+$T:-'L3Y2H(X(QQ6A: +9P*H  C4 #MQ4M^[8
MT2]^_D<OX&_UFO\ _83E_G77$ @@C(-8OA^*.)]1\N-4W73D[1C)]:VJ4W>0
M4U:*1PMM<2>!-1FM+J*1M"N)"\$Z MY#'^$^W_Z_6NK@UO2KF(2PZC:NGJ)5
MX^O/%79(TFC:.5%=&&&5AD$>XKP[QE;PVNO-%;PQPQ@_=C4*.OH*TBE4>NYC
M.3HK35'INJ^-=/M"+;3C_:-^YVQPV_S#/N1_3FN@M))I;2&2XA$,S("\8;=L
M/<9[U@>"[.UAT6*>*VA29QAI%C 8_4UTM1.RT1K#F?O-G)>,/]?;_P"[_4UN
MZ)_R!K;Z'^9J'6HT?RBR*QYY(S5^S55LX@H &WH!3D_<2.6E2:Q4YWW_ . 3
MT445F=QP6H_\C))_UU_K6_XM_P"03'_UV'_H)I;B&(ZODQH27&?E'M5_5D1[
M+YU5L,",C.*V<M8GEPH-0K*^YR&E:])I=N\*Q*X9MV3],?TJS<>*[V9"D*)'
MGNHR:G\B+_GDG_?(K4TJUMV8L8(BPZ$H,BJDX[V,*5/$-*FIV1A:1H4]_.+F
FZ#+#G<2W5_\ /K7:@!5"J  !@ =J6BL9S<F>GA\-&A&RW>[/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
